- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2022–2027 · research · R01
Engineering dendritic cells to target islet antigen to pro-tolerogenic subsets for prevention and treatment of Type 1 Diabetes
Judith Agudo Cantero · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · grant · OCRP
Design and Testing of Dual-Targeted Fine-Tuned Immune-Restoring (DFIR) CAR T-Cell Therapy to Achieve Cures of High-Grade Serous Ovarian Cancer
Wayne Marasco · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2027 · research · R01
Selective disruption of histone deacetylase complexes using protein interaction modulators
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · grant · PRCRP
Comprehensive Evaluation of Immune Function in Patients Receiving Multimodal Therapy for High-Risk Neuroblastoma
Steven Dubois · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2027 · research · R50
Molecular origins and evolution to treatment resistance in genitourinary cancers
Jihye Park · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · research · R21
Prolonged Nightly Fasting as a Behavioral Intervention for Obesity Reduction and the Prevention of Progression in Precursor Multiple Myeloma
Catherine Marinac · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Novel targeted therapies for chronic myelomonocytic leukemia
Roger Vincent Belizaire · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022 · research · Investigator Profile
Cigall Kadoch — HHMI Investigator Profile (2022-Present)
Cigall Kadoch · Dana-Farber Cancer Institute · funded by Howard Hughes Medical Institute
2022–2027 · research · R01
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Regulation and targeting of tumor cell states and plasticity in pancreatic cancer
Srivatsan Raghavan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · research · R03
Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)
Laurie Hollis Glimcher · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · grant · PRCRP
Treatment Options for Metastatic Osteosarcoma
Rani George · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2024 · career development · K99
Defining the landscape and mechanisms of redox regulation of metabolism during aging
Haopeng Xiao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Elucidating the molecular mechanism and physiological relevance of TIRR mediated inhibition of p53
Dipanjan Chowdhury · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · grant · KCRP
Biomarkers of Response to Combination Cabozantinib + Nivolumab in Advanced Renal Cell Carcinoma
Toni Choueiri · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2027 · career development · K08
A Novel Intervention for Avoidance-Related Opioid Misuse in Patients with Cancer
Miryam Yusufov · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Mechanisms and Therapy of Chronic Graft-vs.-Host Disease
Corey S Cutler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Regulation and targeting of tumor cell states and plasticity in pancreatic cancer
Srivatsan Raghavan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
Toni Choueiri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Defining the landscape and mechanisms of protein redox regulation during aging
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Novel Health Equity Intervention to Improve Pediatric Oncology Outcome Disparities: Targeting Poverty and Psychosocial Stress
Kira O. Bona · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Cyclin C-CDK8/19 kinases in development and in cancer
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · research · R21
Prolonged Nightly Fasting as a Behavioral Intervention for Obesity Reduction and the Prevention of Progression in Precursor Multiple Myeloma
Catherine Marinac · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · cooperative agreement · U54
The Center for Therapeutic Targeting of EWS-oncoproteins
Scott A Armstrong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · research · R21
Defining the impact of mutational drivers on the immune microenvironment of CLL
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · cooperative agreement · U54
The Center for Synovial Sarcoma Biology and Therapeutics
Cigall Kadoch · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
Matthew S Davids · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Synthetic lethalities to cell cycle disruption in glioma
Rameen Beroukhim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Molecular prediction of myeloma in African Americans
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R01
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Altered metabolism and machine learning for pancreatic cancer early detection
Michael H. Rosenthal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2029 · research · R35
Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022 · fellowship · F32
Structural and functional investigation into protein degradation by the DCAF16 ubiquitin ligase
Kedar Puvar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2028 · career development · K00
Elucidating the role of RNA splicing in the metastatic seeding and outgrowth of aggressive cancers.
Kimberly Parker · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Cell lineage as an indicator of immune response in neuroblastoma
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · career development · K99
Modeling and Dissecting Epigenetic Drivers of Gliomagenesis
Gilbert J Rahme · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R01
Systematic identification of minor histocompatibility antigens to address GVHD
Vincent Trien-Vinh Ho · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · research · R21
Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · fellowship · F32
Elucidating novel molecular mechanisms of irisin-mediated effects via integrin
Mu A · Dana-Farber Cancer Institute · funded by National Institutes of Health
